Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Mobilisation

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

Bone Marrow Transplantation volume 31, pages 347–351 (2003)Cite this article

Summary:

Cyclophosphamide (CY) combined with granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilise blood progenitor cells to support high-dose therapy in patients with multiple myeloma (MM). The optimal dose of CY in this setting is unknown. We have retrospectively analysed mobilisation efficiency and need for supportive care in 57 patients with newly diagnosed myeloma previously treated with VAD±local radiotherapy. The patients were mobilised either with low-dose CY (LD-CY, 1.2–2 g/m2) (n=25) or intermediate-dose CY (ID-CY, 4 g/m2) (n=32) plus G-CSF. Both regimens proved to be effective in the progenitor cell mobilisation. At least 2×106/kg CD34+ cells were collected from 88% and 84% of the patients with a single apheresis, respectively. Only one patient in the LD-CY group (4%) failed to mobilise vs none in the ID-CY group. Patients mobilised with LD-CY plus G-CSF had less toxicity: fewer hospital days during the mobilisation and apheresis procedures (5 vs 9 days, P<0.001), lower frequency of fever (20 vs 73%, P<0.001) and less need for supportive care including platelet transfusions (0 vs 24%, P=0.004) and days on parenteral antibiotics (0 vs 4 days, P<0.001). While these regimens seem to be equally effective in terms of progenitor cell mobilisation in newly diagnosed patients with MM, LD-CY+G-CSF is preferential because of more optimal resource utilisation and more favourable toxicity profile.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. High-dose therapy in multiple myeloma: a prospective randomized study of the Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard chemotherapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  4. Gratwohl A, Passweg J, Baldomero H et al. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899–916.

    Article  CAS  PubMed  Google Scholar 

  5. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting stem cell collections in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17.

    CAS  PubMed  Google Scholar 

  6. Boiron J-M, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49–55.

    CAS  PubMed  Google Scholar 

  7. Marit G, Thiessard F, Faberes C et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998; 12: 1447–1456.

    Article  CAS  PubMed  Google Scholar 

  8. Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 g/m2 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–697.

    CAS  PubMed  Google Scholar 

  9. Fitoussi O, Perreau V, Boiron JM et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–842.

    Article  CAS  PubMed  Google Scholar 

  10. Armitage S, Hargreaves R, Samson D et al. CD34 counts to predict adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997; 20: 587–591.

    Article  CAS  PubMed  Google Scholar 

  11. Remes K, Matinlauri I, Grenman S et al. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. J Hematother 1997; 6: 13–19.

    Article  CAS  PubMed  Google Scholar 

  12. Russell NH, McQuaker G, Stainer C et al. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935–940.

    Article  CAS  PubMed  Google Scholar 

  13. Bensinger WI, Appelbaum FR, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  PubMed  Google Scholar 

  14. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–145.

    Article  CAS  PubMed  Google Scholar 

  15. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937–941.

    CAS  PubMed  Google Scholar 

  16. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.

    Article  CAS  PubMed  Google Scholar 

  17. Desikan KR, Barlogie B, Jagannath S et al. Comparable engraftment kinetics following peripheral blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547–1553.

    Article  CAS  PubMed  Google Scholar 

  18. Mahe B, Milpied N, Hermouet S et al. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with multiple myeloma and lymphoma. Br J Haematol 1996; 92: 263–268.

    Article  CAS  PubMed  Google Scholar 

  19. Koc O, Gerson S, Cooper B et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte–macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830.

    Article  CAS  PubMed  Google Scholar 

  20. Alegre A, Tomas JF, Martinez-Chamorro C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 1997; 20: 211–217.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

    E Jantunen & T Nousiainen

  2. Department of Medicine, Turku University Central Hospital, Turku, Finland

    M Putkonen & K Remes

  3. TUCH-Laboratories, Turku University Central Hospital, Turku, Finland

    T-T Pelliniemi

  4. Department of Clinical Chemistry, Kuopio University Hospital, Kuopio, Finland

    E Mahlamäki

Authors
  1. E Jantunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Putkonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Nousiainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T-T Pelliniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Mahlamäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Remes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jantunen, E., Putkonen, M., Nousiainen, T. et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 31, 347–351 (2003). https://doi.org/10.1038/sj.bmt.1703840

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703840

Keywords

This article is cited by

Search

Advanced search

Quick links